Kenji Tamura

26PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMolecular medicinePredictive and prognostic markersCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jan 24, 2025
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji

|Sep 09, 2022
First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors.

Satoru Iwasa, Takafumi Koyama, Makoto Nishino

|Jun 27, 2022
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).

Yutaka Yamamoto, Hiroji Iwata, Naruto Taira

|May 13, 2021
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.

Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara

|Apr 30, 2021
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors.

Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori

|Feb 22, 2021
First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors.

Shunsuke Kondo, Toshio Shimizu, Takafumi Koyama

Pageof 5

Frequent Collaborators

6 joint publications

Mayu Yunokawa

4 joint publications

Yutaka Fujiwara

4 joint publications

Kan Yonemori

4 joint publications

Takafumi Koyama